vs
Side-by-side financial comparison of Bluerock Homes Trust, Inc. (BHM) and Journey Medical Corp (DERM). Click either name above to swap in a different company.
Bluerock Homes Trust, Inc. is the larger business by last-quarter revenue ($18.9M vs $16.1M, roughly 1.2× Journey Medical Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -50.1%, a 42.4% gap on every dollar of revenue. On growth, Bluerock Homes Trust, Inc. posted the faster year-over-year revenue change (35.9% vs 27.3%). Over the past eight quarters, Bluerock Homes Trust, Inc.'s revenue compounded faster (30.1% CAGR vs 11.0%).
Bluerock Homes Trust, Inc. is a U.S.-headquartered real estate investment trust that acquires, owns and operates a portfolio of high-quality single-family rental residential properties. It caters to middle-market renters across high-growth suburban markets, prioritizing regions with strong demographic fundamentals and sustained rental housing demand.
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
BHM vs DERM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.9M | $16.1M |
| Net Profit | $-9.5M | $-1.2M |
| Gross Margin | — | — |
| Operating Margin | -48.8% | -2.8% |
| Net Margin | -50.1% | -7.8% |
| Revenue YoY | 35.9% | 27.3% |
| Net Profit YoY | -29.9% | -182.0% |
| EPS (diluted) | $-0.75 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.9M | $16.1M | ||
| Q3 25 | $16.6M | $17.0M | ||
| Q2 25 | $16.8M | $15.0M | ||
| Q1 25 | $16.4M | $13.1M | ||
| Q4 24 | $13.9M | $12.6M | ||
| Q3 24 | $12.7M | $14.6M | ||
| Q2 24 | $12.5M | $14.9M | ||
| Q1 24 | $11.2M | $13.0M |
| Q4 25 | $-9.5M | $-1.2M | ||
| Q3 25 | $-10.0M | $-2.3M | ||
| Q2 25 | $-5.8M | $-3.8M | ||
| Q1 25 | $-7.3M | $-4.1M | ||
| Q4 24 | $-7.3M | $1.5M | ||
| Q3 24 | $3.5M | $-2.4M | ||
| Q2 24 | $-5.2M | $-3.4M | ||
| Q1 24 | $-3.2M | $-10.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 82.3% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 56.0% | ||
| Q1 24 | — | 47.7% |
| Q4 25 | -48.8% | -2.8% | ||
| Q3 25 | -57.6% | -9.0% | ||
| Q2 25 | -30.9% | -19.2% | ||
| Q1 25 | -42.6% | -25.3% | ||
| Q4 24 | -52.8% | 17.7% | ||
| Q3 24 | 27.9% | -19.8% | ||
| Q2 24 | -41.3% | -19.7% | ||
| Q1 24 | -28.4% | -77.4% |
| Q4 25 | -50.1% | -7.8% | ||
| Q3 25 | -60.0% | -13.6% | ||
| Q2 25 | -34.7% | -25.3% | ||
| Q1 25 | -44.7% | -31.0% | ||
| Q4 24 | -52.8% | 12.1% | ||
| Q3 24 | 27.9% | -16.3% | ||
| Q2 24 | -41.3% | -22.6% | ||
| Q1 24 | -28.4% | -80.1% |
| Q4 25 | $-0.75 | $-0.04 | ||
| Q3 25 | $-0.94 | $-0.09 | ||
| Q2 25 | $-0.66 | $-0.16 | ||
| Q1 25 | $-0.67 | $-0.18 | ||
| Q4 24 | $-0.65 | $0.10 | ||
| Q3 24 | $0.24 | $-0.12 | ||
| Q2 24 | $-0.42 | $-0.17 | ||
| Q1 24 | $-0.27 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $169.6M | $24.1M |
| Total DebtLower is stronger | $428.4M | $25.3M |
| Stockholders' EquityBook value | $128.7M | $31.9M |
| Total Assets | $1.2B | $94.6M |
| Debt / EquityLower = less leverage | 3.33× | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $169.6M | $24.1M | ||
| Q3 25 | $2.1M | $24.9M | ||
| Q2 25 | $4.2M | $20.3M | ||
| Q1 25 | $3.0M | $21.1M | ||
| Q4 24 | $115.2M | $20.3M | ||
| Q3 24 | $155.1M | $22.5M | ||
| Q2 24 | $116.0M | $23.9M | ||
| Q1 24 | $92.3M | $24.1M |
| Q4 25 | $428.4M | $25.3M | ||
| Q3 25 | $415.9M | $25.2M | ||
| Q2 25 | $338.6M | $25.1M | ||
| Q1 25 | $336.5M | $25.0M | ||
| Q4 24 | $373.8M | $24.9M | ||
| Q3 24 | $122.5M | $19.8M | ||
| Q2 24 | $119.7M | $19.7M | ||
| Q1 24 | $120.2M | $14.7M |
| Q4 25 | $128.7M | $31.9M | ||
| Q3 25 | $131.7M | $25.9M | ||
| Q2 25 | $135.3M | $19.2M | ||
| Q1 25 | $137.1M | $21.5M | ||
| Q4 24 | $139.1M | $20.1M | ||
| Q3 24 | $142.9M | $10.9M | ||
| Q2 24 | $142.5M | $11.3M | ||
| Q1 24 | $144.5M | $13.0M |
| Q4 25 | $1.2B | $94.6M | ||
| Q3 25 | $222.1M | $85.2M | ||
| Q2 25 | $220.3M | $81.2M | ||
| Q1 25 | $186.2M | $85.0M | ||
| Q4 24 | $967.0M | $80.2M | ||
| Q3 24 | $800.8M | $64.0M | ||
| Q2 24 | $756.2M | $65.2M | ||
| Q1 24 | $727.4M | $66.6M |
| Q4 25 | 3.33× | 0.79× | ||
| Q3 25 | 3.16× | 0.97× | ||
| Q2 25 | 2.50× | 1.30× | ||
| Q1 25 | 2.45× | 1.16× | ||
| Q4 24 | 2.69× | 1.24× | ||
| Q3 24 | 0.86× | 1.81× | ||
| Q2 24 | 0.84× | 1.75× | ||
| Q1 24 | 0.83× | 1.13× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $27.8M | $-6.3M |
| Free Cash FlowOCF − Capex | $10.4M | — |
| FCF MarginFCF / Revenue | 55.0% | — |
| Capex IntensityCapex / Revenue | 91.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $25.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.8M | $-6.3M | ||
| Q3 25 | $13.4M | $-2.4M | ||
| Q2 25 | $13.9M | $-942.0K | ||
| Q1 25 | $951.0K | $-2.8M | ||
| Q4 24 | $9.1M | $2.2M | ||
| Q3 24 | $1.7M | $-1.2M | ||
| Q2 24 | $1.3M | $-5.2M | ||
| Q1 24 | $1.1M | $-5.0M |
| Q4 25 | $10.4M | — | ||
| Q3 25 | $8.7M | — | ||
| Q2 25 | $8.8M | — | ||
| Q1 25 | $-2.9M | — | ||
| Q4 24 | $-253.0K | — | ||
| Q3 24 | $-601.0K | — | ||
| Q2 24 | $-654.0K | — | ||
| Q1 24 | $-630.0K | — |
| Q4 25 | 55.0% | — | ||
| Q3 25 | 52.4% | — | ||
| Q2 25 | 52.2% | — | ||
| Q1 25 | -17.6% | — | ||
| Q4 24 | -1.8% | — | ||
| Q3 24 | -4.7% | — | ||
| Q2 24 | -5.2% | — | ||
| Q1 24 | -5.6% | — |
| Q4 25 | 91.8% | — | ||
| Q3 25 | 28.5% | — | ||
| Q2 25 | 30.3% | — | ||
| Q1 25 | 23.4% | — | ||
| Q4 24 | 66.9% | — | ||
| Q3 24 | 18.0% | — | ||
| Q2 24 | 15.3% | — | ||
| Q1 24 | 15.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | 0.47× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHM
| Residential Communities Segment | $11.4M | 61% |
| Scattered Single Family Homes Segment | $7.5M | 39% |
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
